KeyCorp Research Analysts Decrease Earnings Estimates for Charles River Laboratories International, Inc. (NYSE:CRL)

Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) – Investment analysts at KeyCorp dropped their Q1 2022 EPS estimates for shares of Charles River Laboratories International in a report released on Sunday, April 10th. KeyCorp analyst P. Knight now forecasts that the medical research company will post earnings per share of $2.69 for the quarter, down from their previous estimate of $2.71. KeyCorp has a “Overweight” rating and a $390.00 price objective on the stock. KeyCorp also issued estimates for Charles River Laboratories International’s Q2 2022 earnings at $2.78 EPS and FY2023 earnings at $13.70 EPS.

A number of other brokerages also recently issued reports on CRL. Robert W. Baird reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Monday, December 20th. Stephens started coverage on Charles River Laboratories International in a research report on Wednesday, April 6th. They issued an “overweight” rating and a $377.00 price objective for the company. StockNews.com started coverage on Charles River Laboratories International in a research report on Thursday, March 31st. They issued a “hold” rating for the company. UBS Group lowered their price objective on Charles River Laboratories International from $465.00 to $420.00 and set a “buy” rating for the company in a research report on Thursday, February 17th. Finally, Wells Fargo & Company lowered their price target on Charles River Laboratories International from $450.00 to $390.00 in a research report on Thursday, February 17th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $405.40.

CRL opened at $289.82 on Tuesday. The stock’s fifty day moving average is $291.64 and its two-hundred day moving average is $347.04. The company has a market capitalization of $14.63 billion, a P/E ratio of 38.13, a PEG ratio of 1.86 and a beta of 1.23. Charles River Laboratories International has a 52 week low of $251.30 and a 52 week high of $460.21. The company has a quick ratio of 1.04, a current ratio of 1.23 and a debt-to-equity ratio of 1.05.

Charles River Laboratories International (NYSE:CRLGet Rating) last released its quarterly earnings data on Wednesday, February 16th. The medical research company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.42 by $0.07. The company had revenue of $905.05 million for the quarter, compared to the consensus estimate of $888.27 million. Charles River Laboratories International had a return on equity of 22.38% and a net margin of 11.04%. Charles River Laboratories International’s quarterly revenue was up 14.4% on a year-over-year basis. During the same period last year, the business posted $2.39 EPS.

Institutional investors and hedge funds have recently made changes to their positions in the company. CarsonAllaria Wealth Management Ltd. acquired a new stake in Charles River Laboratories International in the fourth quarter valued at about $27,000. McDonald Partners LLC acquired a new stake in Charles River Laboratories International in the fourth quarter valued at about $28,000. MUFG Americas Holdings Corp acquired a new stake in Charles River Laboratories International in the fourth quarter valued at about $30,000. Jones Financial Companies Lllp lifted its position in Charles River Laboratories International by 200.0% in the third quarter. Jones Financial Companies Lllp now owns 75 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 50 shares during the period. Finally, Clearstead Advisors LLC acquired a new stake in Charles River Laboratories International in the third quarter valued at about $32,000. Institutional investors and hedge funds own 91.37% of the company’s stock.

In related news, EVP Joseph W. Laplume sold 1,143 shares of the stock in a transaction on Friday, February 18th. The stock was sold at an average price of $291.80, for a total value of $333,527.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO James C. Foster sold 20,000 shares of the stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $315.46, for a total value of $6,309,200.00. The disclosure for this sale can be found here. Insiders sold 38,975 shares of company stock worth $11,791,146 over the last quarter. 1.20% of the stock is currently owned by insiders.

Charles River Laboratories International Company Profile (Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Read More

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.